{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:52:38Z","timestamp":1772160758686,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Vertex Pharmaceuticals Incorporated"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>\n                      Predictors of response to treatment with peginterferon plus ribavirin are well established. In these post\u2010hoc analyses of the\n                      <jats:styled-content style=\"fixed-case\">REALIZE<\/jats:styled-content>\n                      study, we sought to identify predictors of response for telaprevir\u2010based triple therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients from the\n                      <jats:styled-content style=\"fixed-case\">REALIZE<\/jats:styled-content>\n                      study with baseline data for all predictors evaluated (including baseline disease characteristics and demographics, prior treatment response and baseline laboratory assessments) were included in the post\u2010hoc analyses (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0465). Univariate and multivariate analyses were used to evaluate factors predicting treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sustained viral response (\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      ) rates were 86% in prior relapsers, 63% in prior partial responders and 32% in prior null\u2010responders. In the final multivariate analysis, baseline factors predicting\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      were prior response to treatment [Odds ratio (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      )\u00a0=\u00a02.80; 95% confidence interval (\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ), 2.13\u20133.69], low\u2010density lipoprotein (\n                      <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n                      ) (\u22652.6\u00a0mmol\/L) (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      \u00a0=\u00a02.11; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      , 1.52\u20132.93),\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      genotype (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      \u00a0=\u00a00.58; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      , 0.36\u20130.93), and maximum alanine amino transferase and aspartate amino transferase (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      \u00a0=\u00a00.62; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      , 0.40\u20130.97).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Prior response to peginterferon plus ribavirin treatment and\n                      <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n                      levels are the main independent predictive markers of response with telaprevir\u2010based triple therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.12703","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T09:57:40Z","timestamp":1413367060000},"page":"448-454","source":"Crossref","is-referenced-by-count":6,"title":["Low\u2010density lipoprotein and other predictors of response with telaprevir\u2010based therapy in treatment\u2010experienced\n                    <scp>HCV<\/scp>\n                    genotype 1 patients:\n                    <scp>REALIZE<\/scp>\n                    study"],"prefix":"10.1111","volume":"35","author":[{"given":"Thomas","family":"Berg","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum Leipzig Sektion Hepatologie Klinik f\u00fcr Gastroenterologie und Rheumatologie Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche Universit\u00e0 di Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes INSERM Unit\u00e9 1016 and Assistance Publique\u2013H\u00f4pitaux de Paris Cochin Hospital Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Alfred Hospital Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zobair","family":"Younossi","sequence":"additional","affiliation":[{"name":"Center for Liver Diseases and Department of Medicine Inova Fairfax Hospital Falls Church Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moises","family":"Diago","sequence":"additional","affiliation":[{"name":"Hospital General de Valencia Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Alamo Medical Research San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Focaccia","sequence":"additional","affiliation":[{"name":"Emilio Ribas Institute of Infectious Diseases S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Queen Marys University of London Institute of Cell and Molecular Science London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw Wolska Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lonjon\u2010Domanec","sequence":"additional","affiliation":[{"name":"Janssen Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"DeMasi","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Titusville New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Titusville New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghan","family":"Luo","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Titusville New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Johann Wolfgang Goethe University Medical Center Frankfurt am Main Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12053"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41403.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03823.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36128"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.126"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02741.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520600955526"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22543"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-011-0458-y"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08463"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.005"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.013"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.449"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.158"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40594"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/507307"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1813-1822.2006"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.023"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26437"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.011"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00091.2007"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.09.024"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/317580"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23592"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25582"},{"issue":"1","key":"e_1_2_8_33_1","first-page":"375A","article-title":"Predictors of virologic response with telaprevir\u2010based combination treatment in HCV genotype 1\u2010infected patients with prior peginterferon\/ribavirin treatment failure: post\u2010hoc analysis of the Phase III REALIZE study","volume":"54","author":"Berg T","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12703","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:46:02Z","timestamp":1695548762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/liv.12703"],"URL":"https:\/\/doi.org\/10.1111\/liv.12703","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.722185478.793500954","asserted-by":"object"}]},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}